Literature DB >> 17643252

Artificial phosphatidylserine liposome mimics apoptotic cells in inhibiting maturation and immunostimulatory function of murine myeloid dendritic cells in response to 1-chloro-2,4-dinitrobenze in vitro.

Dongmei Shi1, Meng Fu, Pinshen Fan, Wei Li, Xinhui Chen, Chenxin Li, Xianlong Qi, Tianwen Gao, Yufeng Liu.   

Abstract

Phosphatidylserine (PS) exposed on the apoptotic cell surface inhibits inflammatory responses, implying that PS may regulate the function of dendritic cells (DCs) after being phagocytosed by the latter. Here we use PS liposomes to investigate the effects of PS on the maturation and immunostimulatory functions of DCs in response to the challenge of 1-chloro-2,4-dinitrobenze (DNCB) in vitro. We demonstrate that after treatment with PS, murine DCs display reduced expression of MHC II, CD80, CD86 and CD40, but increased programmed death ligand-1 (PD-L1 and PD-L2); and increased IL-10 and inhibited IL-12 cytokine production. PS-treated DCs exhibit normal endocytic function, but ability to stimulate allogeneic T cells is reduced, similar to immature dendritic cell (iDCs). Treatment of DCs with PS liposomes also suppressed DNCB induced CD4 + T cell proliferation and IFN-gamma production. Addition of exogenous IL-12p70 during the DC-T cell co-culture restored their IFN-gamma production. Furthermore, PS-treated DCs enhance the ratio of CD4(+) CD25(high)Foxp3(+) T cells to CD4(+) T cells and PD-1 expression on CD4(+) T cells. These data demonstrate that PS liposomes have therapeutic potential in allergic contact dermatitis (ACD).

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17643252     DOI: 10.1007/s00403-007-0770-9

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  9 in total

Review 1.  Ectosomes as modulators of inflammation and immunity.

Authors:  S Sadallah; C Eken; J A Schifferli
Journal:  Clin Exp Immunol       Date:  2010-10-29       Impact factor: 4.330

Review 2.  "Eat me" imaging and therapy.

Authors:  Vaishali Bagalkot; Jeffrey A Deiuliis; Sanjay Rajagopalan; Andrei Maiseyeu
Journal:  Adv Drug Deliv Rev       Date:  2016-01-27       Impact factor: 15.470

3.  Chlamydia trachomatis Cellular Exit Alters Interactions with Host Dendritic Cells.

Authors:  Ashley M Sherrid; Kevin Hybiske
Journal:  Infect Immun       Date:  2017-04-21       Impact factor: 3.441

Review 4.  Therapeutic Liposomal Vaccines for Dendritic Cell Activation or Tolerance.

Authors:  Noémi Anna Nagy; Aram M de Haas; Teunis B H Geijtenbeek; Ronald van Ree; Sander W Tas; Yvette van Kooyk; Esther C de Jong
Journal:  Front Immunol       Date:  2021-05-13       Impact factor: 7.561

5.  Use of autoantigen-loaded phosphatidylserine-liposomes to arrest autoimmunity in type 1 diabetes.

Authors:  Irma Pujol-Autonell; Arnau Serracant-Prat; Mary Cano-Sarabia; Rosa M Ampudia; Silvia Rodriguez-Fernandez; Alex Sanchez; Cristina Izquierdo; Thomas Stratmann; Manuel Puig-Domingo; Daniel Maspoch; Joan Verdaguer; Marta Vives-Pi
Journal:  PLoS One       Date:  2015-06-03       Impact factor: 3.240

Review 6.  Pharmacological Tools to Activate Microglia and their Possible use to Study Neural Network Patho-physiology.

Authors:  Fernando Pena-Ortega
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

Review 7.  Nanoparticle-Based Drug Delivery Systems for Induction of Tolerance and Treatment of Autoimmune Diseases.

Authors:  He Li; Yong-Guang Yang; Tianmeng Sun
Journal:  Front Bioeng Biotechnol       Date:  2022-04-06

8.  Enhancement of Anti-Inflammatory Activity of Curcumin Using Phosphatidylserine-Containing Nanoparticles in Cultured Macrophages.

Authors:  Ji Wang; Yu-Xia Kang; Wen Pan; Wan Lei; Bin Feng; Xiao-Juan Wang
Journal:  Int J Mol Sci       Date:  2016-06-20       Impact factor: 5.923

9.  Enhanced efficacy of curcumin with phosphatidylserine-decorated nanoparticles in the treatment of hepatic fibrosis.

Authors:  Ji Wang; Wen Pan; Ying Wang; Wan Lei; Bin Feng; Caigan Du; Xiao-Juan Wang
Journal:  Drug Deliv       Date:  2018-11       Impact factor: 6.419

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.